Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
09/2010
09/28/2010US7803576 Nucleic acid sequences encoding VEGF-like factors and uses thereof
09/28/2010US7803531 Anticancer, antitumor agents
09/28/2010US7803399 Delivery system for nucleic acids
09/28/2010US7803385 An isolated reovirus comprising a lambda-3 polypeptide, wherein the lambda-3 polypeptide comprises SEQ ID NO:19; muagenesis- directed; antiproliferative agents; anticarcinogenic agents;antitumor agents; kits
09/28/2010US7803379 Tumour-specific animal proteins
09/28/2010CA2382631C Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
09/28/2010CA2285746C Osteoprotegerin binding proteins and receptors
09/23/2010WO2010108177A2 A method and composition using a dual specificity protein tyrosine phosphatase as an antimalarial drug target
09/23/2010WO2010108114A2 Polyunsaturated fatty acid synthase nucleic acid molecules and polypeptides, compositions, and methods of making and uses thereof
09/23/2010WO2010107740A2 Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
09/23/2010WO2010107733A2 Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
09/23/2010WO2010107493A2 Modification of cxcr4 using engineered zinc finger proteins
09/23/2010WO2010107397A1 Modulators of apoptosis and the uses thereof
09/23/2010WO2010106295A1 Use of decorin for increasing muscle mass
09/23/2010WO2010105372A1 Compositions and methods for silencing hepatitis c virus expression
09/23/2010WO2010088537A3 Improved lipid formulation for the delivery of nucleic acids
09/23/2010WO2010086189A3 Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
09/23/2010US20100240881 Therapeutic compositions
09/23/2010US20100240866 Modified gherlin peptides
09/23/2010US20100240740 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
09/23/2010US20100240739 Widespread gene delivery to motor neurons using peripheral injection of aav vectors
09/23/2010US20100240738 Antisense modulation of kinesin-like 1 expression
09/23/2010US20100240737 Enzyme-prodrug therapy for prosthetic joint repair
09/23/2010US20100240735 Pharmaceutical Compositions for Angiogenic Therapy
09/23/2010US20100240734 Methods and compositions for the specific inhibition of gene expression by double-stranded rna
09/23/2010US20100239608 PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS
09/23/2010US20100239607 Compositions for inducing immune responses
09/23/2010US20100239563 Pharmaceutical composition for the prophylaxis and/or treatment of viral diseases
09/23/2010US20100239558 Lipid Hydrolysis Therapy for Atherosclerosis and Related Diseases
09/23/2010US20100239545 Transfection with nucleic acid; insertion
09/23/2010US20100239543 Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
09/23/2010US20100239542 Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
09/23/2010US20100239530 Ifnar2 mutants, their production and use
09/23/2010US20100239499 Methods and compositions for genetic and retinal disease
09/23/2010CA2755639A1 Polyunsaturated fatty acid synthase nucleic acid molecules and polypeptides, compositions, and methods of making and uses thereof
09/23/2010CA2755409A1 Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
09/23/2010CA2755404A1 Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
09/23/2010CA2755192A1 Modification of cxcr4 using engineered zinc finger proteins
09/22/2010EP2230320A1 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
09/22/2010EP2230317A1 Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms
09/22/2010EP2230307A1 Neutrokine alpha
09/22/2010EP2230253A1 A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
09/22/2010EP2229949A1 Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
09/22/2010EP2229411A1 High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
09/22/2010EP1436313B1 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
09/22/2010EP1401853B1 Modulators of pharmacological agents
09/22/2010EP1335938B1 Apolipoprotein construct
09/22/2010CN1612746B Use of HEPCIDIN as a regulator of iron homeostasis
09/22/2010CN101842490A Antigenic compositions and use of same in the targeted delivery of nucleic acids
09/22/2010CN101838650A Development and applications of new human gene FAMLF in human gene recombination, malignant tumor gene detection and specific monoclonal antibody
09/22/2010CN101837134A Chronic myeloid leukemia DNA vaccine BCR/ABL-pIRES-SEA and preparation method and application thereof
09/22/2010CN101837133A Gram positive microbes DNA vaccine and construction and application thereof
09/22/2010CN101837132A HN1 strain gB gene and avian 1L-18 gene combined nucleic acid vaccine of avian infectious laryngotracheitis virus and preparation method thereof
09/22/2010CN101837131A Application of cancer gene ALCl (Anaplasitc Large Cell Lymphoma) in liver cancer treatment
09/22/2010CN101837123A Tumor cell vaccine and preparation method thereof
09/21/2010US7799901 capable of modulating or mediating the FAS receptor ligand or TNF effect on cells carrying FAS receptor or p55 receptor by binding or interacting with MORT-1 (mediators of receptor toxicity) protein
09/21/2010US7799896 Gene expression inhibition via contacting with tyrphostin; liposomes; drug screening
09/21/2010US7799833 System and method for the pretreatment of the endplates of an intervertebral disc
09/21/2010US7799794 Treatment for cardiovascular disease
09/21/2010US7799565 Lipid encapsulated interfering RNA
09/21/2010US7799541 for Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock and sepsis related to cardiac dysfunction
09/21/2010US7799533 Polypeptides, their production and use
09/21/2010US7799529 Nephrin gene and protein
09/21/2010US7799349 Isolating autologous mononuclear cells and transplanting locally into injured tissue
09/21/2010US7799329 Viruses for the treatment of cellular proliferative disorders
09/21/2010US7799324 Using undifferentiated embryonic stem cells to control the immune system
09/21/2010CA2583843C Improved adenoviral vectors and uses thereof
09/21/2010CA2408746C Antisense phosporodiamidate morpholino oligonucleotide inhibition of cytochrome p450 to modulate drug pharmacokinetics
09/21/2010CA2404235C Cell-specific adenovirus vectors comprising an internal ribosome entry site
09/21/2010CA2343074C Akt nucleic acids, polypeptides, and uses thereof
09/21/2010CA2330241C Attenuated pestiviruses
09/21/2010CA2327835C Methods and modified cells for the treatment of cancer
09/21/2010CA2251655C In vivo gene transfer methods for wound healing
09/21/2010CA2234941C Delivery of biologically active polypeptides
09/17/2010CA2658714A1 Hcv-derived polypeptides and uses thereof
09/16/2010WO2010105096A2 Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
09/16/2010WO2010104796A2 Methods of modulating smooth muscle cell proliferation and differentiation
09/16/2010WO2010103284A1 Diagnosis and treatment of cell proliferation and differentiation disorders based on the fmn2 gene
09/16/2010WO2010062762A3 Compositions and methods for reducing the signs of aging of the skin
09/16/2010WO2010059706A3 Translation factors as anti-aging drug targets
09/16/2010WO2010039778A3 Mammalian genes involved in infection
09/16/2010US20100234448 In vivo production of small interfering rnas that mediate gene silencing
09/16/2010US20100234447 Modulation of glucagon receptor expression
09/16/2010US20100234444 Hindered ester-based biodegradable linkers for oligonucleotide delivery
09/16/2010US20100234300 A purified pro-cytolytic peptide; used to treat localized and metastatic prostate cancer; administered intratumorally and/or intraprostatically
09/16/2010US20100234293 Novel Neurotrophic Factors
09/16/2010US20100233810 In vivo production of small interfering rnas that mediate gene silencing
09/16/2010US20100233735 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
09/16/2010US20100233690 Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
09/16/2010US20100233270 Delivery of Oligonucleotide-Functionalized Nanoparticles
09/16/2010US20100233249 Contraceptive methods and compositions related to proteasomal interference
09/16/2010US20100233186 Novel receptor that binds ctla-8
09/16/2010US20100233171 Differential Drug Sensitivity
09/16/2010US20100233169 Methods for treating obesity using fibroblast growth factor-Like polypeptides
09/16/2010US20100233152 Use of HMGB proteins and nucleic acids that code therefor
09/16/2010US20100233127 Targeted vectors for cancer immunotherapy
09/16/2010US20100233126 Polypeptide
09/16/2010US20100233087 Cyp1b1 nucleic acids and methods of use
09/16/2010CA2754603A1 Non-integrating retroviral vector vaccines
09/15/2010EP2228654A2 Diagnosis and prevention of cancer cell invasion
1 ... 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 ... 870